leadf
logo-loader
viewVentriPoint Diagnostics Ltd.

VentriPoint Diagnostics CEO sees version 3 of diagnostic machine as a "game changer"

Ventripoint Diagnostics (CVE: VPT) CEO Dr George Adams sat down with Steve Darling from Proactive Vancouver to talk about the 3rd version of their Ventripoint Medical System and how many purchase orders the company has received in Canada. 

Adams also told Proactive about a recent study that was done at a heart institute in Edmonton and how that may open up a business vertical. 

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.095 CAD

TSX-V:VPT
Market: TSX-V
Market Cap: $6.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Ventripoint Diagnostics new Director sees strong path forward updated VMS system

Ventripoint Diagnostics (CVE: VPT-OTC: VPTDF) New Director Hugh MacNaught joined Steve Darling from Proactive to discuss his new role on the board of the company. He also shares his background and what he brings to the company. MacNaught also shared details about the news VMS technology and...

1 week, 6 days ago

2 min read